Navigation Links
Terumo to simultaneously evaluate Misago self-expanding stent system in the United States and Japan
Date:5/12/2010

SOMERSET, NJ (May 12, 2010) Terumo Medical Corporation, a U.S.-based subsidiary of Terumo Corporation, today announced it has received an investigational device exemption (IDE) conditional approval from the U.S. Food & Drug Administration (FDA) for its Occlusive/Stenotic Peripheral Artery Revascularization Study (OSPREY) in the U.S., which will evaluate the safety and effectiveness of the MISAGO Self-expanding Stent System for use in the superficial femoral artery (SFA). This marks the company's first U.S. clinical trial for a premarket approval (PMA) device. A unique feature of the clinical trial is that it will simultaneously enroll patients in the U.S. and Japan. Referred to as "Medical Device Collaborative Consultation and Review of Premarketing Applications" under the larger "Harmonization by Doing" (HBD) initiative, Terumo's trial was selected as one of two projects to pilot this approach, which is intended to shorten the gap between product approvals in these two significant world healthcare markets.

HBD is an international effort to develop global clinical trials and address regulatory barriers that may be impediments to timely device approvals. This process is a cooperative effort to move both Japan and the U.S. toward international regulatory harmonization. The HBD initiative is a pilot project launched in December 2003 that seeks regulatory convergence between FDA and MHLW-PMDA (Japan's regulatory bodies). The learning obtained in the "proof of concept" trials will assist both regulatory bodies in streamlining the clinical trial process for faster approvals in both countries, as well as promote the idea of global trials for purposes of collecting better data. In this pilot HBD approach, the products will be submitted for review and approval at the same time.

"I believe this approach to shorten the time for new product approvals between the U.S. and Japan is critical and exciting," said Takao Ohki, MD, Chairman and Professor, D
'/>"/>

Contact: Robert Murphy
rmurphy@storchmurphy.com
908-276-0777
The Storch Murphy Group
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. U.S. Physician Demand for Transradial Access Education on the Rise New Transradial Access Site from Terumo Medical Corporation Supports Educational Need
2. Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting
3. Guinness World Records(R) Attempt For Most People Kissing Simultaneously to Take Place This New Years Eve
4. Scientific panel evaluates soy infant formula safety
5. Brandeis studies evaluate visionary approach to improving eyesight
6. VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated
7. CDC Awards Abt Associates Additional Contracts to Evaluate Effectiveness of H1N1 Vaccine
8. Mathematical model can help communities better evaluate sex offender policies
9. Study evaluates costs and benefits of new chemotherapy drugs
10. Study evaluates costs and benefits associated with new colon cancer therapies
11. Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Terumo to simultaneously evaluate Misago self-expanding stent system in the United States and Japan
(Date:7/24/2014)... overweight and obese preschoolers works better when treatment targets ... child is targeted, according to research published this week ... at Buffalo and Women and Children,s Hospital of Buffalo., ... and had one parent who participated in the study ... mass index (BMI) measurements, calculated based on height and ...
(Date:7/24/2014)... 24, 2014 News Facts , ... has achieved certification for compliance with Department of ... by the DoD Information Assurance Certification and Accreditation ... identified within the DoD as the Enterprise Clinical ... designation from the U.S. Army Medical Materiel Agency. ...
(Date:7/24/2014)... material like a medical device or surgical implant is ... According to Northwestern University,s Guillermo Ameer, most of the ... device,s function. , "You will always get an inflammatory ... engineering in Northwestern,s McCormick School of Engineering and Applied ... of Medicine. "A problem with commonly used plastic materials, ...
(Date:7/24/2014)... 2014 A new study led by the Translational ... among bacteria, viruses and the immune system during HIV ... their potential to infect others based on their ... of virus in their semen despite having low levels ... levels of the virus can be found in different ...
(Date:7/24/2014)... 24, 2014 Horizon BCBSNJ’s second annual ... lucky family a rent-free week in a beautiful Lavallette ... 2014. Don’t miss your chance to win a week’s ... to all New Jersey residents, 25 or older.* Residents ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Antioxidant biomaterial promotes healing 2Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
... plague is significantly slowed when it can't make use of ... in St. Louis report in this week's issue of Science. ... plague, which kills in three to four days and potentially ... causes plague, Yersinia pestis, is vulnerable to antibiotics, but by ...
... dehydrogenase (ADH) is one of the major enzymes involved ... at two loci, ADH1B and ADH1C.// ,The ... linked with protection from alcohol dependence, a new study ... ADH1B*3 allele and alcohol-related disorders among Afro-Trinidadians. Findings indicate ...
... inflammatory disorder that causes degeneration of the nerves in ... including muscle// weakness and pain. ,Most ... remission, leading to the suggestion that there are regulatory ... model of MS (known as EAE), researchers from the ...
... Corps is to get a mega centre with multi-specialities, ... for this here Thursday.// ,The facility will ... (Research & Referral) and will be known as Army ... under one roof facilities for training dental officers, specialists ...
... (Zyban) and nortriptyline double a person’s chances //of giving ... reuptake inhibitors (SSRIs) such as fluoxetine (Prozac) are not ... to help people quit smoking, not everyone is helped ... alternative is to use antidepressants. The rationale for this ...
... India - Dr. Avul Pakir Jainulabdeen Abdul Kalam released ... Shri - on the eve of the Republic Day. ... Committee’ makes the final recommendations on awardees after receiving ... central ministries and departments and institutions of excellence, and ...
Cached Medicine News:Health News:Disabling Key Protein may Give Physicians Time to Treat Pneumonic Plague 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 3Health News:Majority of Padma Awards Go to Doctors from Delhi 2
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2Alimera Sciences To Release Second Quarter 2014 Results 2
... in LDL-C when Treated with 300 mg/week ISIS 301012 ... for 13 Weeks, - Study Presented in Poster Session Today at DALM Symposium in New York ... City, - Isis Will Host a Conference ... at http://www.isispharm.com , ...
... today,announced that the company has been awarded a ... and Technology (NIST) to develop a Sensor,System on ... markers in,a single assay. Successful development of ... of multifactorial conditions such as autoimmune disease and,allergy, ...
Cached Medicine Technology:Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 6Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 2Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 3Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 4
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein G - 50 OD...
Polyester ribbon impregnated with conjugated Protein G - .25 OD per sq. cm....
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: